Lucid Diagnostics

LUCD · NASDAQ

$0.3519−$0.0255 (−6.76%)TodayMarket closed ·
Prev close $0.3774

Key indicators

LUCD profitability and balance sheet ratios

EPS -$0.0638 in Q2 FY26, against -$0.0448 a year earlier.

EPS by quarter
PeriodEPS
Q3 FY24-$0.2456
Q4 FY24-$0.1975
Q1 FY25-$0.3911
Q2 FY25-$0.0448
Q3 FY25-$0.0961
Q4 FY25-$0.1238
Q1 FY26-$0.0993
Q2 FY26-$0.0638

Where the money went

Q2 FY26, from revenue to net income

Lucid Diagnostics brought in $1.5M of revenue in Q2 FY26, +26.7% on a year earlier. It made a net loss of $14.7M.

Revenue
$1.5M
Costs, expenses and taxes
$16.2M
Net income
−$14.7M
Net margin
-998.3%

Income statement

Revenue and profit by reporting period

Revenue
Net income
LUCD income statement, quarterly
Line itemQ4 FY25Q1 FY26Q2 FY26
Revenue$1.5M$1.3M$1.5M
Gross profit−$0.4M−$0.4M$0.0M
Operating income−$14.0M−$12.1M−$12.8M
Net income−$16.3M−$23.6M−$14.7M
Diluted EPS-$0.12-$0.17-$0.08

Balance sheet

What the company owns and owes at period end

Total assets
Total liabilities
LUCD balance sheet, quarterly
Line itemDec 2025Mar 2026Jun 2026
Total assets$40.4M$34.1M$38.9M
Total liabilities$29.5M$30.1M$28.0M
Shareholder equity$10.9M$4.0M$10.9M
Cash and short-term investments$34.7M$27.9M$33.4M
Total debt$24.0M$25.2M$23.5M

Cash flow

Cash in and out from operations, investing and financing

Operating
Investing
Financing
LUCD cash flow, quarterly
Line itemQ4 FY25Q1 FY26Q2 FY26
Operating cash flow−$12.6M−$12.1M−$11.3M
Investing cash flow−$0.1M−$0.2M−$0.0M
Financing cash flow$0.0M$5.5M$16.8M
Capital expenditure−$0.1M−$0.2M−$0.0M
Free cash flow−$12.6M−$12.3M−$11.3M

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.